289 related articles for article (PubMed ID: 22179204)
1. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.
Miyazaki M; Kato M; Tanaka K; Tanaka M; Kohjima M; Nakamura K; Enjoji M; Nakamuta M; Kotoh K; Takayanagi R
Mol Med Rep; 2012 Mar; 5(3):729-33. PubMed ID: 22179204
[TBL] [Abstract][Full Text] [Related]
2. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.
Baumeier C; Schlüter L; Saussenthaler S; Laeger T; Rödiger M; Alaze SA; Fritsche L; Häring HU; Stefan N; Fritsche A; Schwenk RW; Schürmann A
Mol Metab; 2017 Oct; 6(10):1254-1263. PubMed ID: 29031724
[TBL] [Abstract][Full Text] [Related]
3. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes.
Aso Y; Terasawa T; Kato K; Jojima T; Suzuki K; Iijima T; Kawagoe Y; Mikami S; Kubota Y; Inukai T; Kasai K
Transl Res; 2013 Nov; 162(5):309-16. PubMed ID: 23994650
[TBL] [Abstract][Full Text] [Related]
4. Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population.
Zheng T; Chen B; Yang L; Hu X; Zhang X; Liu H; Qin L
Metabolism; 2017 Aug; 73():125-134. PubMed ID: 28637594
[TBL] [Abstract][Full Text] [Related]
5. Hepatic DPP4 DNA Methylation Associates With Fatty Liver.
Baumeier C; Saussenthaler S; Kammel A; Jähnert M; Schlüter L; Hesse D; Canouil M; Lobbens S; Caiazzo R; Raverdy V; Pattou F; Nilsson E; Pihlajamäki J; Ling C; Froguel P; Schürmann A; Schwenk RW
Diabetes; 2017 Jan; 66(1):25-35. PubMed ID: 27999105
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide.
Long Z; Cao M; Su S; Wu G; Meng F; Wu H; Liu J; Yu W; Atabai K; Wang X
Free Radic Biol Med; 2017 Dec; 113():71-83. PubMed ID: 28942246
[TBL] [Abstract][Full Text] [Related]
7. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Firneisz G; Varga T; Lengyel G; Fehér J; Ghyczy D; Wichmann B; Selmeci L; Tulassay Z; Rácz K; Somogyi A
PLoS One; 2010 Aug; 5(8):e12226. PubMed ID: 20805868
[TBL] [Abstract][Full Text] [Related]
8. Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance.
Ahmed RH; Huri HZ; Muniandy S; Al-Hamodi Z; Al-Absi B; Alsalahi A; Razif MF
Clin Biochem; 2017 Sep; 50(13-14):746-749. PubMed ID: 28288852
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.
Ben-Shlomo S; Zvibel I; Shnell M; Shlomai A; Chepurko E; Halpern Z; Barzilai N; Oren R; Fishman S
J Hepatol; 2011 Jun; 54(6):1214-23. PubMed ID: 21145820
[TBL] [Abstract][Full Text] [Related]
10. Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients.
Hu Y; Liu J; Dong X; Xu Y; Leng S; Wang G
Med Sci Monit; 2016 Nov; 22():4146-4151. PubMed ID: 27803497
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
Lee M; Shin E; Bae J; Cho Y; Lee JY; Lee YH; Lee BW; Kang ES; Cha BS
Sci Rep; 2020 Nov; 10(1):19429. PubMed ID: 33173107
[TBL] [Abstract][Full Text] [Related]
12. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease.
Barchetta I; Ceccarelli V; Cimini FA; Barone E; Sentinelli F; Coluzzi M; Chiappetta C; Bertoccini L; Tramutola A; Labbadia G; Di Cristofano C; Silecchia G; Leonetti F; Cavallo MG
J Endocrinol Invest; 2021 May; 44(5):979-988. PubMed ID: 32852705
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis.
Ben-Shlomo S; Zvibel I; Rabinowich L; Goldiner I; Shlomai A; Santo EM; Halpern Z; Oren R; Fishman S
Dig Dis Sci; 2013 Jan; 58(1):172-8. PubMed ID: 22918684
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression.
Trzaskalski NA; Vulesevic B; Nguyen MA; Jeraj N; Fadzeyeva E; Morrow NM; Locatelli CA; Travis N; Hanson AA; Nunes JR; O'Dwyer C; van der Veen JN; Lorenzen-Schmidt I; Seymour R; Pulente SM; Clément AC; Crawley AM; Jacobs RL; Doyle MA; Cooper CL; Kim KH; Fullerton MD; Mulvihill EE
JCI Insight; 2023 Jan; 8(2):. PubMed ID: 36472923
[TBL] [Abstract][Full Text] [Related]
15. Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis.
Mulvihill EE; Varin EM; Gladanac B; Campbell JE; Ussher JR; Baggio LL; Yusta B; Ayala J; Burmeister MA; Matthews D; Bang KWA; Ayala JE; Drucker DJ
Cell Metab; 2017 Jan; 25(1):152-165. PubMed ID: 27839908
[TBL] [Abstract][Full Text] [Related]
16. Plasma DPP4 Activities Are Associated With Osteoporosis in Postmenopausal Women With Normal Glucose Tolerance.
Zheng T; Yang L; Liu Y; Liu H; Yu J; Zhang X; Qin S
J Clin Endocrinol Metab; 2015 Oct; 100(10):3862-70. PubMed ID: 26259132
[TBL] [Abstract][Full Text] [Related]
17. Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
Chen L; Zhang X; Zhang L; Zheng D
Diabetes Metab Syndr Obes; 2020; 13():3507-3518. PubMed ID: 33116702
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl Peptidase 4 Activity Is Related to Body Composition, Measures of Adiposity, and Insulin Resistance in Subjects with Excessive Adiposity and Different Degrees of Glucose Tolerance.
Silva Júnior WS; Souza MDGC; Nogueira Neto JF; Bouskela E; Kraemer-Aguiar LG
J Diabetes Res; 2019; 2019():5238013. PubMed ID: 30886868
[TBL] [Abstract][Full Text] [Related]
19. DPP4 deletion in adipose tissue improves hepatic insulin sensitivity in diet-induced obesity.
Romacho T; Sell H; Indrakusuma I; Roehrborn D; Castañeda TR; Jelenik T; Markgraf D; Hartwig S; Weiss J; Al-Hasani H; Roden M; Eckel J
Am J Physiol Endocrinol Metab; 2020 May; 318(5):E590-E599. PubMed ID: 31891536
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes.
Rufinatscha K; Radlinger B; Dobner J; Folie S; Bon C; Profanter E; Ress C; Salzmann K; Staudacher G; Tilg H; Kaser S
Biochem Biophys Res Commun; 2017 Apr; 485(2):366-371. PubMed ID: 28213130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
